– First validation of a gene expression classifier in pre-treatment biopsy samples from prospective randomized trials –
San Francisco, CA (UroToday.com) — Veracyte, Inc., announced that new data being presented at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting suggest the company’s Decipher Prostate genomic classifier identifies patients with clinically high-risk prostate cancer who may require treatment intensification beyond standard-of-care therapy.